Literature DB >> 2742853

Binding of placental ribonuclease inhibitor to the active site of angiogenin.

F S Lee1, B L Vallee.   

Abstract

The importance of specific residues in angiogenin for binding to placental ribonuclease inhibitor (PRI) has been assessed by examining the interaction of angiogenin derivatives with PRI. PRI binds native angiogenin with a Ki value of 7.1 X 10(-16) M [Lee, F. S., Shapiro, R., & Vallee, B. L. (1989) Biochemistry 28, 225-230]. Substitution of a Gln for Lys-40 in angiogenin by site-specific mutagenesis decreases the association rate constant 3-fold and increases the dissociation rate constant 440-fold, resulting in a 1300-fold weaker Ki value. The half-life of the mutant.PRI complex is 3.4 h compared to approximately 60 days for the native angiogenin.PRI complex. The magnitude of the change in Ki value suggests that in the complex, Lys-40 forms a salt bridge or hydrogen bond with an anionic moiety in PRI. Carboxymethylation of His-13 or His-114 with bromoacetate increases the Ki value 15-fold, and oxidation of Trp-89 by means of dimethyl sulfoxide and hydrochloric acid increases it 2.4-fold, suggesting that these residues also form part of the contact region with PRI. The changes in Ki value reflect an increase in the dissociation rate constant. On the other hand, dinitrophenylation of either Lys-50 or Lys-60 with 1-fluoro-2,4-dinitrobenzene does not significantly alter the Ki value, suggesting that these residues are not part of the contact region. These results indicate that PRI inhibition minimally involves the three residues critical for the activity of angiogenin--Lys-40, His-13, and His-114--and to a lesser extent its single tryptophan, Trp-89.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2742853     DOI: 10.1021/bi00434a061

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.

Authors:  A C Papageorgiou; R Shapiro; K R Acharya
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  Knockdown of ribonuclease inhibitor expression with siRNA in non-invasive bladder cancer cell line BIU-87 promotes growth and metastasis potentials.

Authors:  Junxia Chen; Xi Ou-Yang; Juan Gao; Jun Zhu; Xiaoyan He; Jiang Rong
Journal:  Mol Cell Biochem       Date:  2010-12-02       Impact factor: 3.396

3.  Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography.

Authors:  D D Leonidas; G B Chavali; A M Jardine; S Li; R Shapiro; K R Acharya
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

Review 4.  RNA biology of angiogenin: Current state and perspectives.

Authors:  Shawn M Lyons; Marta M Fay; Yasutoshi Akiyama; Paul J Anderson; Pavel Ivanov
Journal:  RNA Biol       Date:  2017-02       Impact factor: 4.652

5.  Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.

Authors:  C Z Chen; R Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  Structural basis for catalysis by onconase.

Authors:  J Eugene Lee; Euiyoung Bae; Craig A Bingman; George N Phillips; Ronald T Raines
Journal:  J Mol Biol       Date:  2007-10-04       Impact factor: 5.469

7.  Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.

Authors:  Xiaojing Cong; Christian Cremer; Thomas Nachreiner; Stefan Barth; Paolo Carloni
Journal:  Protein Sci       Date:  2016-05-19       Impact factor: 6.725

8.  Crystal structures of murine angiogenin-2 and -3-probing 'structure--function' relationships amongst angiogenin homologues.

Authors:  Shalini Iyer; Daniel E Holloway; K Ravi Acharya
Journal:  FEBS J       Date:  2012-12-11       Impact factor: 5.542

9.  Crystal structure of human angiogenin with an engineered loop exhibits conformational flexibility at the functional regions of the molecule.

Authors:  Nethaji Thiyagarajan; K Ravi Acharya
Journal:  FEBS Open Bio       Date:  2012-12-26       Impact factor: 2.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.